5 results on '"Lee, Brian K"'
Search Results
2. Acetaminophen Use During Pregnancy and Children's Risk of Autism, ADHD, and Intellectual Disability.
- Author
-
Ahlqvist, Viktor H., Sjöqvist, Hugo, Dalman, Christina, Karlsson, Håkan, Stephansson, Olof, Johansson, Stefan, Magnusson, Cecilia, Gardner, Renee M., and Lee, Brian K.
- Subjects
- *
INTELLECTUAL disabilities , *NOSOLOGY , *ACETAMINOPHEN , *AUTISM , *AUTISTIC children , *ATTENTION-deficit hyperactivity disorder - Abstract
Key Points: Question: Does acetaminophen use during pregnancy increase children's risk of neurodevelopmental disorders? Findings: In this population-based study, models without sibling controls identified marginally increased risks of autism and attention-deficit/hyperactivity disorder (ADHD) associated with acetaminophen use during pregnancy. However, analyses of matched full sibling pairs found no evidence of increased risk of autism (hazard ratio, 0.98), ADHD (hazard ratio, 0.98), or intellectual disability (hazard ratio, 1.01) associated with acetaminophen use. Meaning: Acetaminophen use during pregnancy was not associated with children's risk of autism, ADHD, or intellectual disability in sibling control analyses. This suggests that associations observed in other models may have been attributable to confounding. Importance: Several studies suggest that acetaminophen (paracetamol) use during pregnancy may increase risk of neurodevelopmental disorders in children. If true, this would have substantial implications for management of pain and fever during pregnancy. Objective: To examine the associations of acetaminophen use during pregnancy with children's risk of autism, attention-deficit/hyperactivity disorder (ADHD), and intellectual disability. Design, Setting, and Participants: This nationwide cohort study with sibling control analysis included a population-based sample of 2 480 797 children born in 1995 to 2019 in Sweden, with follow-up through December 31, 2021. Exposure: Use of acetaminophen during pregnancy prospectively recorded from antenatal and prescription records. Main Outcomes and Measures: Autism, ADHD, and intellectual disability based on International Classification of Diseases, Ninth Revision and International Classification of Diseases, Tenth Revision codes in health registers. Results: In total, 185 909 children (7.49%) were exposed to acetaminophen during pregnancy. Crude absolute risks at 10 years of age for those not exposed vs those exposed to acetaminophen were 1.33% vs 1.53% for autism, 2.46% vs 2.87% for ADHD, and 0.70% vs 0.82% for intellectual disability. In models without sibling control, ever-use vs no use of acetaminophen during pregnancy was associated with marginally increased risk of autism (hazard ratio [HR], 1.05 [95% CI, 1.02-1.08]; risk difference [RD] at 10 years of age, 0.09% [95% CI, −0.01% to 0.20%]), ADHD (HR, 1.07 [95% CI, 1.05-1.10]; RD, 0.21% [95% CI, 0.08%-0.34%]), and intellectual disability (HR, 1.05 [95% CI, 1.00-1.10]; RD, 0.04% [95% CI, −0.04% to 0.12%]). To address unobserved confounding, matched full sibling pairs were also analyzed. Sibling control analyses found no evidence that acetaminophen use during pregnancy was associated with autism (HR, 0.98 [95% CI, 0.93-1.04]; RD, 0.02% [95% CI, −0.14% to 0.18%]), ADHD (HR, 0.98 [95% CI, 0.94-1.02]; RD, −0.02% [95% CI, −0.21% to 0.15%]), or intellectual disability (HR, 1.01 [95% CI, 0.92-1.10]; RD, 0% [95% CI, −0.10% to 0.13%]). Similarly, there was no evidence of a dose-response pattern in sibling control analyses. For example, for autism, compared with no use of acetaminophen, persons with low (<25th percentile), medium (25th-75th percentile), and high (>75th percentile) mean daily acetaminophen use had HRs of 0.85, 0.96, and 0.88, respectively. Conclusions and Relevance: Acetaminophen use during pregnancy was not associated with children's risk of autism, ADHD, or intellectual disability in sibling control analysis. This suggests that associations observed in other models may have been attributable to familial confounding. This nationwide cohort study with sibling control analysis examines the association of acetaminophen use during pregnancy with children's risk of autism, ADHD, and intellectual disability. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Maternal intrahepatic cholestasis of pregnancy and neurodevelopmental conditions in offspring: A population-based cohort study of 2 million Swedish children.
- Author
-
Chen, Shuyun, Ahlqvist, Viktor H., Sjöqvist, Hugo, Stephansson, Olof, Magnusson, Cecilia, Dalman, Christina, Karlsson, Håkan, Lee, Brian K., and Gardner, Renee M.
- Subjects
- *
CHILDREN with intellectual disabilities , *NEURAL development , *PREGNANCY outcomes , *MATERNAL age , *BIRTH order , *INTELLECTUAL disabilities - Abstract
Background: Intrahepatic cholestasis of pregnancy (ICP) is the most common obstetric liver disorder and is associated with an increased risk of iatrogenic preterm birth and adverse infant outcomes. Hence, there are several plausible pathways through which ICP could affect offspring neurodevelopment. However, to the best of our knowledge, no studies have investigated these associations. Thus, we aimed to determine whether ICP is associated with offspring neurodevelopmental conditions. Methods and findings: In this Swedish register-based cohort study, we included singleton non-adopted children born in Sweden between the 1st of January 1987 and the 31st of December 2010, who were resident in Sweden >5 years, with no missing covariate information, which we followed until the 31st of December 2016. Maternal ICP diagnosis and the date of the initial diagnosis during pregnancy were obtained from the National Patient Register. Offspring diagnoses of attention deficit/hyperactivity disorder (ADHD), autism, or intellectual disability were obtained from the National Patient Register, and the dispensation of ADHD medications were obtained from the Prescribed Drug Register. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression while controlling for observed confounders and unobserved confounders shared among full siblings and maternal full cousins. A total of 2,375,856 children were included in the study; 81.6% of them were of Nordic origin, and 51.4% were male. Of these, 10,378 (0.44%) were exposed to ICP. During a median of 18 years follow-up (interquartile range 11 to 24), 143,746 (6.05%) of children were diagnosed with a neurodevelopmental condition. After adjusting for child's sex, birth year, birth month, maternal age, highest parental education level, maternal birth country, birth order, maternal psychiatric history, ICP was associated with increased odds of offspring neurodevelopmental conditions (OR 1.22, 95% CI 1.13 to 1.31), particularly among those exposed to early-onset ICP (OR 2.38, 95% CI 1.71 to 3.30) as compared to ICP diagnosed after reaching term (≥37 weeks of gestation) (OR 1.08, 95% CI 0.97 to 1.20). The findings of early-onset ICP were consistent in family-based analyses. Within-family comparisons of full maternal cousins yielded an OR of 2.99 (95% CI 1.48 to 6.04), and comparisons of full siblings showed an OR of 1.92 (95% CI 0.92 to 4.02), though the latter was less precise. The findings were consistent across specific neurodevelopmental conditions and different analytical approaches. The primary limitations of this study included its observational design, the absence of data on ICP therapeutics, and the lack of bile acid measures. Conclusions: In this study, we observed that exposure to ICP during gestation is associated with an increased likelihood of neurodevelopmental conditions in offspring, particularly in cases of early-onset ICP. Further studies are warranted to better understand the role of early-ICP in offspring neurodevelopment. In this Swedish register-based cohort study, Shuyun Chen, Viktor H. Ahlqvist and colleagues assess the association between maternal intrahepatic cholestasis of pregnancy and neurodevelopmental disorders in children exposed during gestation. Author summary: Why was this study done?: Intrahepatic cholestasis of pregnancy (ICP) is a common liver disorder during pregnancy characterized by rising bile acid levels, and it is associated with early delivery and adverse infant outcomes. Less is known about the long-term outcomes of children exposed to ICP. Because ICP may plausibly affect the development of the fetus either directly or via its association with adverse pregnancy outcomes, this study examined the hypothesis that ICP would be associated with an increased likelihood of neurodevelopmental conditions in children exposed during gestation. What did the researchers do and find?: The study analyzed data from the Swedish registers including children born between 1987 and 2010, with follow-up for neurodevelopmental outcomes until the end of 2016. The study recorded cases of mothers diagnosed with ICP and documented the timing of these diagnoses during pregnancy using patient registries. Associations between these diagnoses and neurodevelopmental conditions, including attention deficit/hyperactivity disorder (ADHD), autism, or intellectual disability in children, were estimated using multiple analytical approaches. The results suggested that children exposed to ICP during pregnancy were more likely to receive diagnoses of neurodevelopmental conditions, particularly when ICP was diagnosed early in pregnancy (before 28 weeks of gestation). Because the associations were similar when children were compared to their maternal cousins and to their siblings, these findings do not appear to be explained by factors shared within families, such as genetics and some aspects of the early life environment, that can also influence the likelihood of neurodevelopmental conditions. What do these findings mean?: Diagnosis of ICP during pregnancy, especially early in pregnancy, is associated with an increased likelihood of neurodevelopmental disorders in the children exposed during gestation. Because this study is observational, it is not possible to determine whether ICP is a causative factor in the development of neurodevelopmental conditions in children born to affected mothers. This study did not include information on bile acid concentrations among the pregnant women, and this study was conducted before treatment (using ursodeoxycholic acid) was widely used in Sweden. It will be important for future studies to consider if therapeutic modulation of bile acid levels in pregnant women affected by ICP can mitigate the associations we observe. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Psychiatric comorbidities in epilepsy: population co-occurrence, genetic correlations and causal effects.
- Author
-
Ahlqvist, Viktor H., Dardani, Christina, Madley-Dowd, Paul, Forbes, Harriet, Rast, Jessica, Caichen Zhong, Gardner, Renee M., Dalman, Christina, Lyall, Kristen, Newschaffer, Craig, Tomson, Torbjörn, Lundberg, Michael, Berglind, Daniel, Davies, Neil M., Lee, Brian K., Magnusson, Cecilia, and Rai, Dheeraj
- Subjects
- *
EPILEPSY , *PARTIAL epilepsy , *GENOME-wide association studies , *COMORBIDITY , *PEOPLE with epilepsy , *GENETIC correlations - Abstract
Background Psychiatric comorbidities are common in patients with epilepsy. Reasons for the co-occurrence of psychiatric conditions and epilepsy remain poorly understood. Aim We aimed to triangulate the relationship between epilepsy and psychiatric conditions to determine the extent and possible origins of these conditions. Methods Using nationwide Swedish health registries, we quantified the lifetime prevalence of psychiatric disorders in patients with epilepsy. We then used summary data from genome-wide association studies to investigate whether the identified observational associations could be attributed to a shared underlying genetic aetiology using cross-trait linkage disequilibrium score regression. Finally, we assessed the potential bidirectional relationships using two-sample Mendelian randomisation. Results In a cohort of 7 628 495 individuals, we found that almost half of the 94 435 individuals diagnosed with epilepsy were also diagnosed with a psychiatric condition in their lifetime (adjusted lifetime prevalence, 44.09%; 95% confidence interval (CI) 43.78% to 44.39%). We found evidence for a genetic correlation between epilepsy and some neurodevelopmental and psychiatric conditions. For example, we observed a genetic correlation between epilepsy and attention-deficit/hyperactivity disorder (rg=0.18, 95% CI 0.09 to 0.27, p<0.001)--a correlation that was more pronounced in focal epilepsy (rg=0.23, 95% CI 0.09 to 0.36, p<0.001). Findings from Mendelian randomisation using common genetic variants did not support bidirectional effects between epilepsy and neurodevelopmental or psychiatric conditions. Conclusions Psychiatric comorbidities are common in patients with epilepsy. Genetic correlations may partially explain some comorbidities; however, there is little evidence of a bidirectional relationship between the genetic liability of epilepsy and psychiatric conditions. These findings highlight the need to understand the role of environmental factors or rare genetic variations in the origins of psychiatric comorbidities in epilepsy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Trends and patterns of antiseizure medication prescribing during pregnancy between 1995 and 2018 in the United Kingdom: A cohort study.
- Author
-
Madley‐Dowd, Paul, Rast, Jessica, Ahlqvist, Viktor H., Zhong, Caichen, Martin, Florence Z., Davies, Neil M., Lyall, Kristen, Newschaffer, Craig, Tomson, Torbjörn, Magnusson, Cecilia, Rai, Dheeraj, Lee, Brian K., and Forbes, Harriet
- Subjects
- *
DURATION of pregnancy , *PREGNANCY , *DRUGS , *COHORT analysis , *MEDICAL research - Abstract
Objective: To examine antiseizure medication (ASM) prescription during pregnancy. Design: Population‐based drug utilisation study. Setting: UK primary and secondary care data, 1995–2018, from the Clinical Practice Research Datalink GOLD version. Population or Sample: 752 112 completed pregnancies among women registered for a minimum of 12 months with an 'up to standard' general practice prior to the estimated start of pregnancy and for the duration of their pregnancy. Methods: We described ASM prescription across the study period, overall and by ASM indication, examined patterns of prescription during pregnancy including continuous prescription and discontinuation, and used logistic regression to investigate factors associated with those ASM prescription patterns. Main Outcome Measures: Prescription of ASMs during pregnancy and discontinuation of ASMs before and during pregnancy. Results: ASM prescription during pregnancy increased from 0.6% of pregnancies in 1995 to 1.6% in 2018, driven largely by an increase in women with indications other than epilepsy. Epilepsy was an indication for 62.5% of pregnancies with an ASM prescription and non‐epilepsy indications were present for 66.6%. Continuous prescription of ASMs during pregnancy was more common in women with epilepsy (64.3%) than in women with other indications (25.3%). Switching ASMs was infrequent (0.8% of ASM users). Factors associated with discontinuation included age ≥35, higher social deprivation, more frequent contact with the GP and being prescribed antidepressants or antipsychotics. Conclusions: ASM prescription during pregnancy increased between 1995 and 2018 in the UK. Patterns of prescription around the pregnancy period vary by indication and are associated with several maternal characteristics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.